Document:

Exhibit 4.2

THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”). 

NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.  IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT.  “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE 1933 ACT. 

THE HOLDER OF THE SECURITIES REPRESENTED HEREBY MUST NOT TRADE SUCH SECURITIES IN OR FROM A JURISDICTION OF CANADA UNLESS THE CONDITIONS IN SECTION 13 OF MULTILATERAL INSTRUMENT 51-105 ISSUERS QUOTED IN THE U.S. OVER-THE-COUNTER MARKETS ARE MET.

STOCK OPTION AGREEMENT 

(Non U.S. Person)

This AGREEMENT is entered into as of the u day of u, 2018 (the “Date of Grant”).

BETWEEN:

BLOX, INC., a company incorporated pursuant to the laws of the State of Nevada, with an office located at #202 – 5626 Larch Street, Vancouver, British Columbia, Canada V6M 4E1

(the “Company”)

AND:

u

(the “Optionee”)

WHEREAS:

A.

The Company’s board of directors (the “Board”) has approved and adopted the 2014 Stock Option Plan (the “Plan”) whereby the Board is authorized to grant stock options to purchase shares of common stock of the Company to the directors, officers, employees and consultants of the Company and its subsidiaries; 

B.

The Optionee is a director, officer, employee or consultant of the Company or subsidiary of the Company; and

C.

The Company wishes to grant stock options to purchase a total of u Optioned Shares (as defined herein) to the Optionee.

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

2

1.

DEFINITIONS

1.1

In this Agreement, the following terms shall have the following meanings:

(a)

“1933 Act” means the United States Securities Act of 1933, as amended;

(b)

“Applicable Laws” means all legal requirements relating to the Plan or the Securities under applicable United States federal and state securities laws, the United States Internal Revenue Code,  Canadian provincial securities laws, the Income Tax Act (Canada), the rules of any applicable stock exchange or stock quotation system, and any other applicable laws of any jurisdiction;

(c)

“Exercise Price” means an aggregate price of $u.

(d)

“Expiry Date” means u;

(e)

“Notice of Exercise” means a completed and executed notice in writing delivered to the Company at its address first recited hereto (or such other address of which the Company may from time to time notify the Optionee in writing), in the form attached as Schedule “A” hereto, which notice shall specify therein the number of Optioned Shares in respect of which the Options are being exercised;

(f)

“Options” means the irrevocable right and option to purchase, from time to time, all, or any part of the Optioned Shares granted to the Optionee by the Company pursuant to Section 2.1 of this Agreement;

(g)

“Optioned Shares” means the Shares that are issued pursuant to the exercise of any Options;

(h)

“Securities” means, collectively, the Options and the Optioned Shares;

(i)

“Shareholders” means holders of record of Shares;

(j)

“Shares” means shares in the common stock of the Company;

(k)

“U.S. Person” shall have the meaning ascribed thereto in Regulation S under the 1933 Act, and for the purpose of the Agreement includes any person in the United States; and

(l)

“Vested Options” means the Options that have vested in accordance with Section 2.2 of this Agreement.

1.2

Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Plan.

2.

THE OPTIONS

2.1

The Company hereby grants to the Optionee, on the terms and conditions set out in this Agreement and in the Plan, Options to purchase a total of u Optioned Shares at the Exercise Price, provided that any grant or exercise of any Options to or by an Optionee will be conditional on compliance with all Applicable Law.  

2.2

The Option shall vest according to the following: EXERCISABLE IMMEDIATELY 

2.3

The Options may be exercised immediately after vesting.

2.4

The Options shall, at 5:00 p.m. (Pacific time) on the Expiry Date, expire and be of no further force or effect whatsoever.

2.5

The Company shall not be obligated to cause the issuance, transfer or delivery of a certificate or certificates representing Optioned Shares to the Optionee until provision has been made by the Optionee, to the satisfaction of the Company, for the payment of the aggregate Exercise Price for all Optioned Shares for which the Options shall have been exercised, and for satisfaction of any withholding obligations associated with such exercise.

3

2.6

The Optionee shall have no rights whatsoever as a shareholder in respect of any of the Optioned Shares (including any right to receive dividends or other distribution therefrom or thereon) except in respect of which the Options have been properly exercised in accordance with the terms of this Agreement.

2.7

The Options will terminate in accordance with the provisions of the Plan.

2.8

Subject to the provisions of this Agreement and the Plan and subject to compliance with any applicable securities laws, the Options shall be exercisable, in full or in part, at any time after vesting, until termination, provided that if the Optionee is subject to the reporting and liability provisions of Section 16 of the Securities Exchange Act of 1934, as amended, the Optionee shall be precluded from selling, transferring or otherwise disposing of any Optioned Shares during the six months immediately following the grant of the Options unless an exemption is available to such restrictions.  If less than all of the Optioned Shares included in the vested portion of any Options are purchased, the remainder may be purchased at any subsequent time prior to the Expiry Date.  Only whole Optioned Shares may be issued pursuant to the exercise of any Options, and to the extent that any Option covers less than one Optioned Share, it is not exercisable.

2.9

Each exercise of the Options shall be by means of delivery of a completed and executed Notice of Exercise (in the form attached hereto as Schedule “A”) by the Optionee to the Chief Financial Officer of the Company at its principal executive office, specifying the number of Optioned Shares to be purchased and accompanied by payment in cash, by wire transfer or, if the funds are draw from a Canadian bank, by certified cheque, in the amount of the full Exercise Price for the Optioned Shares to be purchased or in such other manner as permitted by the Plan.  

2.10

It is a condition precedent to the issuance of Optioned Shares that the Optionee execute and/or deliver to the Company all documents and withholding taxes required in accordance with Applicable Laws.

2.11

Nothing in this Agreement shall obligate the Optionee to purchase any Optioned Shares except those Optioned Shares in respect of which the Optionee shall have exercised the Options in the manner provided in this Agreement or the Plan. 

2.12

The terms of the Options are subject to the provisions of the Plan, as the same may from time to time be amended, and any inconsistencies between this Agreement and the Plan, as the same may be from time to time amended, shall be governed by the provisions of the Plan.

2.13

By accepting the Options, the Optionee represents and agrees that none of the Optioned Shares purchased upon exercise of the Options will be distributed in violation of any Applicable Laws.  The Optionee further represents and agrees to provide the Company with any other document reasonably requested by the Company or the Company’s legal counsel.

3.

DOCUMENTS REQUIRED FROM OPTIONEE

3.1

The Optionee must complete, sign and return an executed copy of this Agreement to the Company.

3.2

The Optionee shall complete, sign and return to the Company, as soon as practicable on request by the Company, any documents, questionnaires, notices and undertakings as may be required by regulatory authorities and Applicable Laws.

4.

SUBJECT TO STOCK OPTION PLAN

The terms of the Options will be subject to the Plan, as may from time to time be amended, and any inconsistencies between this Agreement and the Plan, as the same may be from time to time amended, shall be governed by the provisions of the Plan.  A copy of the Plan will be delivered to the Optionee, and will be available for inspection at the principal offices of the Company.

5.

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE OPTIONEE

The Optionee hereby represents and warrants to and covenants with the Company (which representations, warranties and covenants shall survive the closing) that:

(a)

the Optionee is a director, officer, employee or consultant of the Company or subsidiary of the Company;

(b)

if the Optionee is a consultant and resident in Canada, the Optionee:

4

(i)

is engaged to provide services to the Company or a related entity of the Company, other than services provided in relation to a distribution, 

(ii)

provides the services under a written contract with the Company or a related entity of the issuer, and 

(iii)

spends or will spend a significant amount of time and attention on the affairs and business of the issuer or a related entity of the issuer;

(c)

if an employee or consultant of the Company or subsidiary of the Company, the Optionee is a bona fide employee or consultant of the Company or subsidiary of the Company;

(d)

the Optionee understands and agrees none of the Securities have been or will be registered under the 1933 Act, or under any state securities or “blue sky” laws of any state of the United States, and, unless so registered, may not be offered or sold in the United States or, directly or indirectly, to U.S. Persons, as that term is defined in Regulation S under the 1933 Act (“Regulation S”), except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in each case only in accordance with applicable state and foreign securities laws;

(e)

the Optionee is not a U.S. Person and is not acquiring the Securities for the account or benefit of, directly or indirectly, any U.S. Person;

(f)

is outside the United States when receiving and executing this Agreement;

(g)

the Optionee understands and agrees that offers and sales of any of the Securities prior to the expiration of the period specified in Regulation S (such period hereinafter referred to as the “Distribution Compliance Period”) shall only be made in compliance with the safe harbor provisions set forth in Regulation S, pursuant to the registration provisions of the 1933 Act or an exemption therefrom, and that all offers and sales after the Distribution Compliance Period shall be made only in compliance with the registration provisions of the 1933 Act or an exemption therefrom and in each case only in accordance with applicable state and provincial securities laws; 

(h)

the Optionee acknowledges that it has not acquired the Securities as a result of, and will not itself engage in, any “directed selling efforts” (as defined in Regulation S under the 1933 Act) in the United States in respect of any of the Securities which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Securities; provided, however, that the Optionee may sell or otherwise dispose of any of the Securities pursuant to registration of any of the Securities pursuant to the 1933 Act and any applicable securities laws or under an exemption from such registration requirements and as otherwise provided herein; 

(i)

hedging transactions involving the Securities may not be conducted unless such transactions are in compliance with the provisions of the 1933 Act and in each case only in accordance with applicable securities laws;

(j)

the Optionee has the legal capacity and competence to enter into and execute this Agreement and to take all actions required pursuant hereto;

(k)

the Optionee is resident in the jurisdiction set out on page 1 of this Agreement;

(l)

the Optionee:

(i)

is knowledgeable of, or has been independently advised as to, the applicable securities laws of the securities regulators having application in the jurisdiction in which the Optionee is resident (the “International Jurisdiction”) which would apply to the granting of the Option; 

5

(ii)

the Optionee is acquiring the Option pursuant to exemptions from prospectus or equivalent requirements under applicable securities laws or, if such is not applicable, the Optionee is permitted to acquiring the Option under the applicable securities laws of the securities regulators in the International Jurisdiction without the need to rely on any exemptions;

(iii)

the applicable securities laws of the authorities in the International Jurisdiction do not require the Company to make any filings or seek any approvals of any kind whatsoever from any securities regulator of any kind whatsoever in the International Jurisdiction in connection with the granting of the Option; 

(iv)

the granting of the Option by the Company does not trigger:

A.

any obligation to prepare and file a prospectus or similar document, or any other report with respect to such purchase in the International Jurisdiction; or

B.

any continuous disclosure reporting obligation of the Optionee or the Company in the International Jurisdiction; and

(v)

the Optionee will, if requested by the Company, deliver to the Company a certificate or opinion of local counsel from the International Jurisdiction which will confirm the matters referred to in subparagraphs (ii), (iii) and (iv) above to the satisfaction of the Company, acting reasonably;

(m)

the acquisition of the Securities by the Optionee as contemplated in this Agreement complies with or is exempt from the applicable securities legislation of the jurisdiction of residence of the Optionee; and

(n)

the Optionee understands and agrees that the Company and others will rely upon the truth and accuracy of the acknowledgements, representations and agreements contained in this Agreement, and agrees that if any of such acknowledgements, representations and agreements are no longer accurate or have been breached, the Optionee shall promptly notify the Company.

6.

LEGENDING OF SUBJECT SECURITIES

6.1

The Optionee hereby consents to the placement of a legend on any certificate or other document evidencing any of the Optioned Shares to the effect that such Optioned Shares have not been registered under the 1933 Act or any state securities or “blue sky” laws, are subject to resale restrictions in Canada, and setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement, such legends to be substantially as follows:

THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”). 

NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT.

THE HOLDER OF THE SECURITIES REPRESENTED HEREBY MUST NOT TRADE SUCH SECURITIES IN OR FROM A JURISDICTION OF CANADA UNLESS THE CONDITIONS IN SECTION 13 OF MULTILATERAL INSTRUMENT 51-105 ISSUERS QUOTED IN THE U.S. OVER-THE-COUNTER MARKETS ARE MET.

6

6.2

The Optionee hereby agrees to the Company making a notation on its records or giving instructions to the registrar and transfer agent of the Company in order to implement the restrictions on transfer set forth and described in this Agreement.

7.

GENERAL RESALE RESTRICTIONS

7.1

The Optionee acknowledges that any resale of any of the Securities will be subject to resale restrictions contained in the securities legislation applicable to the Optionee or proposed transferee.  The Optionee acknowledges that none of the Securities have been registered under the 1933 Act or the securities laws of any state of the United States.  The Securities may not be offered or sold in the United States unless registered in accordance with federal securities laws and all applicable state securities laws or exemptions from such registration requirements are available.

7.2

The Optionee acknowledges that the Securities are subject to resale restrictions in Canada and may not be traded in Canada except as permitted by the applicable provincial securities laws and the rules made thereunder.

7.3

If the Optionee is not a resident of Canada, the Optionee represents, warrants and acknowledges that:

(a)

pursuant to Multilateral Instrument 51-105 – Issuers Quoted in the U.S. Over-the-Counter Markets (“MI 51-105”), a subsequent trade in the Securities in or from Canada will be a distribution subject to the prospectus and registration requirements of applicable Canadian securities legislation unless certain conditions are met, which conditions include, among others, a requirement that any certificate representing the Securities (or ownership statement issued under a direct registration system or other book entry system) bear the restrictive legend (the “Canadian Legend”) specified in MI 51-105;

(b)

the Optionee is not a resident of British Columbia and undertakes not to trade or resell any of the Shares in or from British Columbia unless the trade or resale is made in accordance with MI 51-105.  The Optionee understands and agrees that the Company and others will rely upon the truth and accuracy of these representations and warranties made in this Section 7.2 and agrees that if such representations and warranties are no longer accurate or have been breached, the Optionee shall immediately notify the Company;

(c)

by executing and delivering this Agreement, the Optionee will have directed the Company not to include the Canadian Legend on any certificates representing the Securities to be issued to the Optionee. As a consequence, the Optionee will not be able to rely on the resale provisions of MI 51-105, and any subsequent trade in any of the Securities in or from Canada will be a distribution subject to applicable prospectus and registration requirements; and

(d)

if the Optionee wishes to trade or resell any of the Securities in or from Canada, the Optionee agrees and undertakes to return, prior to any such trade or resale, any certificate representing any Securities to the Company’s transfer agent to have the Canadian Legend imprinted on such certificate or to instruct the Company’s transfer agent to include the Canadian Legend on any ownership statement issued under a direct registration system or other book entry system.

7.4

The Optionee acknowledges and agrees that the Optionee is solely responsible (and the Company is not in any way responsible) for compliance with applicable resale restrictions.

8.

NO EMPLOYMENT RELATIONSHIP

The grant of an Option shall in no way constitute any form of agreement or understanding binding on the Company or any Related Company (as defined in the Plan), express or implied, that the Company or any Related Company will employ or contract with the Optionee, for any length of time, nor shall it interfere in any way with the Company’s or, where applicable, a Related Company’s right to terminate the Optionee’s employment at any time, which right is hereby reserved.

9.

GOVERNING LAW

This Agreement is governed by the laws of the State of Nevada.

7

10.

COSTS

The Optionee acknowledges and agrees that all costs and expenses incurred by the Optionee (including any fees and disbursements of any special counsel retained by the Optionee) relating to the acquisition of the Securities shall be borne by the Optionee.

11.

SURVIVAL

This Agreement, including without limitation the representations, warranties and covenants contained herein, shall survive and continue in full force and effect and be binding upon the parties hereto notwithstanding the completion of the purchase of any Optioned Shares by the Optionee pursuant hereto.

12.

ASSIGNMENT

This Agreement is not transferable or assignable.

13.

CURRENCY

Unless explicitly stated otherwise, all funds in this Agreement are stated in United States dollars.

14.

SEVERABILITY

The invalidity or unenforceability of any particular provision of this Agreement shall not affect or limit the validity or enforceability of the remaining provisions of this Agreement.

15.

COUNTERPARTS AND ELECTRONIC MEANS

This Agreement may be executed in several counterparts, each of which will be deemed to be an original and all of which will together constitute one and the same instrument.  Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date first above written.

16.

ENTIRE AGREEMENT

This Agreement is the only agreement between the Optionee and the Company with respect to the Securities, and this Agreement and the Plan supersede all prior and contemporaneous oral and written statements and representations and contain the entire agreement between the parties with respect to the Securities.

IN WITNESS WHEREOF the parties hereto have duly executed this Agreement as of the date first above written.

BLOX, INC.

Per:

Authorized Signatory

Name & Title of Signatory

u

Per:  

        Signature

SCHEDULE “A”

NOTICE OF EXERCISE

TO:

Blox, Inc.

#202 – 5626 Larch Street, 

Vancouver, British Columbia, Canada V6M 4E1

This Notice of Exercise shall constitute a proper Notice of Exercise pursuant to Section 2.9 of the Stock Option Agreement dated as of ____________________ (the “Agreement”) between Blox, Inc. (the “Company”) and the Optionee.  The Optionee hereby elects to exercise its option to purchase ____________________ shares of the common stock of the Company at a price of US $______ per share, for aggregate consideration of US $____________, on the terms and conditions set forth in the Agreement.  Such aggregate consideration, in the form specified in Section 2.9 of the Agreement, accompanies this Notice of Exercise.  

The Optionee represents and warrants to the Company that all representations and warranties set out in the Agreement are true as of the date of this Notice of Exercise.

Please deliver a share certificate to the Optionee in respect of such Optioned Shares as are to be issued upon exercise of the number of Options provided for in this Notice of Exercise. 

The Optionee hereby directs the Company to issue, register and deliver the certificates representing the Optioned Shares as follows:

			
	Registration Information:

	 
	Delivery Instructions:

	 
	 
	 

	Name to appear on certificates

	 
	Name

	 
	 
	 

	Address

	 
	Address

	 
	 
	 

	City, State, and Zip Code

	 
	 

	 
	 
	 

	 
	Telephone Number

Capitalized terms used in this Notice of Exercise and not otherwise defined herein shall have the meanings ascribed thereto in the Agreement.

DATED at _____________________________, the  day of______________, _______.

	
	X

	Signature

	 

	(Name and, if applicable, Office)

	 

	(Address)

	 

	(City, State, and Zip Code)

	 

	Fax Number or E-mail Address

	 

	SIN, SSN or Other Tax Identification NumberExhibit
10.6

 

THESE
SHARES ARE BEING OFFERED UNDER AN EXEMPTION FROM REGISTRATION PURSUANT TO SECTION 4(a)(2) OF THE SECURITIES ACT OF 1933 AS AMENDED
OR SECURITIES AND EXCHANGE COMMISSION REGULATION D, RULE 506(c) PROMULGATED THEREUNDER. WHETHER THESE SHARES ARE EXEMPT FROM REGISTRATION
PURSUANT TO REGULATION D OR OTHERWISE HAS NOT BEEN PASSED UPON BY THE SECURITIES AND EXCHANGE COMMISSION, THE ATTORNEY GENERAL
OF ANY STATE OR ANY OTHER REGULATORY AGENCY, NOR HAS ANY SUCH AGENCY PASSED UPON THE MERITS OF THIS OFFERING. ANY REPRESENTATION
TO THE CONTRARY OR ANY REPRESENTATION THAT ANY REGULATORY AGENCY HAS PASSED UPON THE ACCURACY OR COMPLETENESS OF THIS PRIVATE
PLACEMENT MEMORANDUM IS A CRIMINAL OFFENSE.

 

 

REACH
GENETICS, INC.

 

CONFIDENTIAL
PRIVATE PLACEMENT MEMORANDUM

 

 

1,000,000
SHARES OF COMMON STOCK

Price
Per Share: $1.00

Maximum
Offering: $ 1,000,000

 

REACH
GENETICS, INC. (or the “Company”) hereby offers (the “Offering”) for sale to Accredited Investors a maximum
of 1,000,000 Shares of its Common Stock ($.0001 par value) at a purchase price of $1.00 per Share. The Shares will be sold pursuant
to Regulation D, Rule 506(c), and Section 4(a)(2), exemptions from registration provided by the Securities Act of 1933, as amended.
The Company has the right to withdraw, limit or terminate this Offering at any time and to reject any and all offers to purchase
Shares. Proceeds from the sale of Shares will be immediately available to the Company when received and accepted. There is no
minimum number of Shares required to be sold. The Offering will be terminated when the Company has sold the maximum Offering or
on June 30, 2018, if it has not been sooner terminated or extended, subject to the reserved right of the Company to extend theOffering.

 

	 	 	Principal
    Amount	 	 	Commissions
    (1)	 	 	Proceeds
    to

    Company (2)	 
	Total
    Maximum	 	$	1,000,000	 	 	$	100,000	 	 	$	900,000	 

		(1)	The
                                         Company has agreed to pay sales commissions of 10% to qualified finders and broker/dealers.

 

		(2)	Before
                                         deducting other estimated Offering expenses of approximately $25,000

 

This
Memorandum Is Revised and Dated May 11, 2018

 

    	 	 	 

     

    

 

INVESTOR
DISCLOSURES

 

THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND ARE BEING OFFERED WITHIN THE UNITED STATES PURSUANT TO SECTION
4(a)(2) OF THE SECURITIES ACT AND RULE 506(c) OF REGULATION D PROMULGATED THEREUNDER. THE SECURITIES OFFERED HEREBY MAY NOT BE
OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF IN THE UNITED STATES OR TO “U.S. PERSONS” (AS SUCH TERM
IS DEFINED IN REGULATION S PROMULGATED UNDER THE SECURITIES ACT), EXCEPT PURSUANT TO (1) AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT, (2) REGULATION S UNDER THE SECURITIES ACT, (3) RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE), SUBJECT TO
RECEIPT BY THE COMPANY OF SUCH EVIDENCE (INCLUDING, WITHOUT LIMITATION, OPINIONS OF COUNSEL) ACCEPTABLE TO IT THAT SUCH REOFFER,
RESALE, TRANSFER, PLEDGE OR OTHER DISPOSITION WILL BE EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, OR (4)
ANY OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, SUBJECT TO THE RECEIPT OF SUCH CERTIFICATION AS
THE COMPANY MAY REQUEST, IF APPLICABLE, AND IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE
UNITED STATES. IN ADDITION, EACH PURCHASER OF SHARES WILL BE REQUIRED TO EXECUTE A SUBSCRIPTION AGREEMENT, WHICH IMPOSES SIGNIFICANT
RESTRICTIONS ON THE TRANSFER OF THE SHARES.

 

IN
NO EVENT SHALL THIS MEMORANDUM BE DEEMED TO BE AN OFFER TO ANY PERSON OTHER THAN THE PERSON TO WHOM IT IS ADDRESSED.

 

THIS
MEMORANDUM IS SUBMITTED IN CONNECTION WITH THE PRIVATE PLACEMENT OF THE SHARES AND MAY NOT BE REPRODUCED OR USED FOR ANY OTHER
PURPOSE.

 

OWNERSHIP
OF THE SHARES OFFERED HEREBY INVOLVES A HIGH DEGREE OF RISK.

 

THE
COMPANY HAS AGREED TO MAKE AVAILABLE, PRIOR TO THE CONSUMATION OF THE TRANSACTION CONTEMPLATED HEREIN, TO EACH OFFEREE OF INTERESTS
AND ITS REPRESENTATIVE(S) THE OPPORTUNITY TO ASK QUESTIONS OF, AND RECEIVE ANSWERS FROM THE COMPANY OR ANY PERSON ACTING ON ITS
BEHALF CONCERNING THE TERMS AND CONDITIONS OF THIS OFFERING, AND TO OBTAIN ANY ADDITIONAL INFORMATION, TO THE EXTENT IT POSSESSES
SUCH INFORMATION OR CAN ACQUIRE IT WITHOUT UNREASONABLE EFFORT OR EXPENSE, NECESSARY TO VERIFY THE ACCURACY OF THE INFORMATION
SET FORTH HEREIN.

 

THERE
ARE NO TAX BENEFITS FROM AN INVESTMENT IN THE COMPANY AND ANY INVESTMENT SHOULD BE MADE SOLELY FOR ECONOMIC REASONS.

 

PROSPECTIVE
INVESTORS ARE NOT TO CONSTRUE THE CONTENTS OF THIS MEMORANDUM OR ANY PRIOR OR SUBSEQUENT COMMUNICATION FROM THE COMPANY, ITS OFFICER,
DIRECTORS, AFFILIATES, OR ANY PROFESSIONAL ASSOCIATED WITH THIS OFFERING, AS LEGAL, TAX OR INVESTMENT ADVICE. EACH INVESTOR SHOULD
CONSULT WITH AND RELY ON ITS OWN COUNSEL, ACCOUNTANT AND OTHER ADVISERS AS TO LEGAL, TAX AND ECONOMIC IMPLICATIONS OF THE INVESTMENT
DESCRIBED HEREIN AND ITS SUITABILITY.

 

    	 	 	2 | Page

     

    

 

NO
REPRESENTATION OR WARRANTY IS OR CAN BE MADE AS TO THE ECONOMIC RETURN THAT MAY ACCRUE TO AN INVESTOR.

 

 

 

NO
DISTRIBUTION OF THIS MEMORANDUM IN WHOLE OR IN PART, OR THE DIVULGENCE OF ANY OF ITS CONTENTS, IS PERMITTED UNLESS AUTHORIZED
BY THE COMPANY. NO OFFERING LITERATURE OR ADVERTISING IN WHATEVER FORM SHALL BE EMPLOYED IN THE OFFERING OF THESE SHARES, EXCEPT
THE INFORMATION CONTAINED HEREIN OR AUTHORIZED BY THE COMPANY. NO PERSON HAS BEEN AUTHORIZED TO MAKE REPRESENTATIONS, OR GIVE
ANY INFORMATION, WITH RESPECT TO THE SHARES, EXCEPT THE INFORMATION CONTAINED HEREIN.

 

 

 

THIS
MEMORANDUM DOES NOT CONSTITUTE AN OFFER OR SOLICITATION TO ANYONE IN ANY STATE OR IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR
SOLICITATION IS NOT AUTHORIZED.

 

 

 

REFERENCE
SHOULD BE MADE TO THE SUPPORTING DOCUMENTS AND OTHER INFORMATION FURNISHED HEREWITH FOR THE COMPLETE INFORMATION CONCERNING THE
RIGHTS AND OBLIGATIONS OF THE PARTIES THERETO. CERTAIN PROVISIONS OF SUCH AGREEMENTS ARE SUMMARIZED IN THIS MEMORANDUM, BUT IT
SHOULD NOT BE ASSUMED THAT THE SUMMARIES ARE COMPLETE AND THERE CAN BE NO GUARANTEE THAT SUCH INFORMATION OR THAT CIRCUMSTANCES
HAVE NOT CHANGED SINCE THE DATE OF SUCH INFORMATION AND ANY UNDERLYING ASSUMPTIONS WEREPROVIDED.

 

NASAA
UNIFORM LEGEND

 

IN
MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING
THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY
AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE
STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO
BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

 

    	 	 	3 | Page

     

    

 

SUMMARY
OF OFFERING

 

THIS
SUMMARY IS INTENDED ONLY FOR GENERAL REFERENCE. NOT ALL THE MATERIAL FACTS RELATING TO THIS INVESTMENT APPEAR IN THIS SUMMARY.
THE MEMORANDUM AND EXHIBITS ATTACHED HERETO DESCRIBE IN DETAIL NUMEROUS ASPECTS OF THE TRANSACTION WHICH ARE MATERIAL TO PROSPECTIVE
INVESTORS, INCLUDING ASPECTS SUMMARIZED HEREIN, AND OTHER DOCUMENTS ATTACHED HERETO SHOULD BE READ AND UNDERSTOOD IN THEIR ENTIRETY
BY THE PROSPECTIVE INVESTORS.

 

	THE
    COMPANY:	REACH
                                         Genetics, Inc. (the “Company”) was organized pursuant to the laws of the
                                         State of Nevada in October 2015 as AdvantaMeds Solutions USA Fund I, Inc., and in May
                                         2017 the Company changed its name to Doyen Elements, Inc. and in May of 2018 the Company
                                         changed its name to REACH Genetics, Inc. The Company was organized for the purposes of
                                         providing consulting, incubator services, and accelerator services to companies operating
                                         nationally. Upon the completion of this Offering, we intend to focus our business operations
                                         on providing a wide range of services to the legal Industrial Hemp industry, including
                                         property acquisition, leasing, management consulting, genetic research and cultivating
                                         large Hemp Farms to produce high quality products in the United States, as well as to
                                         acquire existing companies which

        are
        currently engaged in providing services to this industry.

	 	 
	TYPE
    OF SECURITY:	The
    Company hereby offers (the “Offering”) for sale to Accredited Investors a maximum of 1,000,000 Shares of Common
    Stock ($.0001 par value) at a purchase price of $1.00 per Share (the “Shares”).
	 	 
	MINIMUM
    SUBSCRIPTION:	There
    is a minimum subscription of 10,000 Shares, for a minimum purchase price of $10,000. The Company reserves the right to reject
    in whole or in part subscriptions received during the Offering.

 

    	 	 	4 | Page

     

    

 

	RISK
    FACTORS:	This
                                         investment involves various and substantial risks, including the risks more particularly
                                         described in this Memorandum.

                                                                                 

	USE
    OF PROCEEDS:	The
                                         Company intends to use the proceeds of this Offering for business development, marketing,
                                         hiring additional employees and for working capital and general corporate purposes.

                                                                               

	SUBSCRIPTION
    PROCEDURES:	As
                                         a condition to accepting subscriptions (i) a Subscription Agreement in the form furnished
                                         by the Company and annexed hereto as Exhibit A must be executed by each prospective investor
                                         and delivered to the Company and (ii) good funds must be delivered by check or wire transfer
                                         in the amount of the purchase price of the Shares being purchased and payable to the
                                         Company.

         

        The
        Company will cause to be delivered to a purchaser whose Subscription Agreement and funds have been accepted by the Company,
        a Subscription Agreement duly authorized and executed by the Company which shall specify the principal sum of Shares purchased
        and consideration paid, which the Company has agreed to sell at such price to such purchasers, along with a Certificate
        representing the Shares purchased.

         

        Each
        prospective investor should obtain the advice of his attorney, tax consultant, and investment advisor with respect to
        the legal, tax and investment aspects of this investment prior to subscribing for the Shares.

         

        The
        Company, in its sole discretion, may accept or reject any potential purchaser’s Subscription Agreement in whole
        or in part, irrespective of whether such potential purchaser meets the standards for investing in the Offering. The Company
        is also under no obligation to accept a potential purchaser’s Subscription Agreement at the Closing.

 

    	 	 	5 | Page

     

    

 

BUSINESS
SUMMARY

 

OVERVIEW

 

REACH
Genetics, Inc. (the “Company”) was organized pursuant to the laws of the State of Nevada in October 2015 as AdvantaMeds
Solutions USA Fund I, Inc., and in May 2017 the Company changed its name to Doyen Elements, Inc. and in May of 2018 the Company
changed its name to REACH Genetics, Inc. The Company was organized for the purposes of providing consulting, incubator services,
and accelerator services to companies operating nationally. Upon the completion of this Offering, we intend to focus our business
operations on providing a wide range of services to the legal Industrial Hemp industry, including property acquisition, leasing,
management consulting, genetic research and cultivating large Hemp Farms to produce high quality products in the United States,
as well as to acquire existing companies which are currently engaged in providing services to this industry. We are a development-stage
and emerging-growth Company and have conducted minimal business operations since our inception.

 

Our
principal business office is located at 4800 Baseline Road, E104-#345, Boulder, CO 80303. Our telephone number is (855) 369-3687,
and our corporate website is www.reachgenetics.com.

 

OUR
MISSION AND VISION

 

Regenerative
Environmental Applications to Cultivate Hemp.

 

REACH
Genetics, Inc. is driven far beyond the bottom-line, it’s the goal to provide products of the highest quality while contributing
to the sustainability of the communities with the privilege of serving. REACH’s management does not import mystery plants
or buy seeds from unreliable sources. The Company is founded on the principal of organically grown hemp that shows promise for
so many. REACH’s own proprietary seed bank allows oversights on every plant, on every farm, from seed to harvest and beyond.
REACH Genetics, Inc.’s plants have been developed to have a superior phytochemical profile known anywhere in the hemp industry
with the purpose of creating healthy supplements and environments.

 

OUR
PRODUCTS AND SERVICES

 

We
have organized our Company to provide a wide range of ancillary services to Industrial Hemp businesses, including real estate
leasing services, management consulting, genetic research, provide large Hemp Farms to produce high quality products and insurance.
We intend to be a “one- stop shop” for the legal Industrial Hemp industry. We expect that operators in this industry
will be able to simplify their business operations, become more efficient, and maximize their profit potential by using our Company’s
variety of ancillary products and services.

 

We
believe that providing ancillary products and services to the licensed legal Industrial Hemp industry puts us in the best position
to tap the national and international market, because we will not be bound by the licensing and regulatory requirements which
binds growers and dispensers to a single state or geographic area. Our goal, and our opportunity, is to provide our products and
services to clients in every state in which Hemp products are legal.

 

    	 	 	6 | Page

     

    

 

These
products and services will include:

 

PRODUCTS:

 

We
currently sell our Premium Whole Plant Extract (CBD oil) called Farmers Hemp Extract in 500 and 1000mg with Zero THC.

 

REAL
ESTATE SERVICES:

 

We
intend to acquire real estate and asset facilities which we can develop or retro-fit for the Company’s grow or other licensed
legal hemp growers and distributors. According to available industry information, there is a significant demand for such facilities
which is not currently being met by the commercial real estate industry. In addition, the supply of legal hemp friendly facilities
and agricultural real estate is rapidly increasing in value in key markets such as Oregon. Through our pending acquisitions, we
will be able to enter this market as a product manufacturer ad grower.

 

CONSULTING
AND MANAGEMENT SERVICES:

 

Through
our pending acquisitions, we have acquired 4 scientists, each of whom has between 10 to 25 years of operational experience in
the legal industrial hemp industry. We intend to offer both established industry participants as well as start-up operators a
wide variety of management and operational services, including licensing, compliance, growth structure, facility build-out and
expansion.

 

Starting
a grow site is typically extremely complex, with varying rules, regulations, and legal risks involved. Because of the experience
of our management and employees, we believe that our Company can provide valuable assistance and guidance.

 

OUR
RECENT ACQUISITIONS

 

REACH
Genetics, Inc., on December 14, 2017, entered into an equity purchase agreement to acquire 7GENx LLC, a Boulder, Colorado based
Hemp genetics research and Development Company for $4,200,000 pursuant to a promissory note due May 21, 2019.

 

7GENx
LLC focuses on creating proprietary hemp cultivators to meet the current and emerging market demands for use in breeding for agricultural,
industrial and medical purposes. Its team of scientists collect data and analysis the chemical, genetic and phenotypic profiles
of hemp, allowing the company to create proprietary varieties of hemp that are targeted for specific uses for current or emerging
markets. Additionally, 7GENx intends to restore regenerative hemp-based agriculture, food, fuel and fiber economies for the health,
safety and welfare of the planet by providing small select farms in Colorado (and other states with state approved hemp programs)
with hemp cultivation and harvesting techniques, elevated organic methods and practices, and proprietary rich hemp oil extract
varieties that meet state hemp program standards.

 

On
January 26, 2018: Termination of Contract

 

Based
on recent developments within REACH Genetics Inc. and the Cannabis industry, we have determined that in order to maximize shareholder
value we are going to more narrowly focus our efforts in the specific areas of hemp related products. Therefore, we will not be
moving forward with the acquisition of the companies owned by Cassaundra McGinnis, Natalie Romolt, Angela Morton, Jeremy Pollock
and Kyle Wendland; in various businesses related to the cannabis industry, pursuant to an agreement dated April 20, 2017.

 

    	 	 	7 | Page

     

    

 

Those
companies operate within the overall cannabis space but outside our updated / more focused strategy. We are continuing to review
other partners or acquisitions consistent with our objectives.

 

SALES
AND MARKETING

 

REACH
Genetics, Inc.’s management is currently targeting hemp companies and certified organic real estate property, strategically
positioning the Company across the globe. While REACH Genetics, Inc. intends to revolutionize the hemp industry through plant
breeding and genetics, the expansion of its research labs and genetic scientists will enable trading on a global level through
the distribution of popular hemp cultivars. The Company’s specialty CBD oils along with branded hemp retail products and
“Hempcrete” construction goods, empowers a marketplace with unlimited solutions.

 

MARKETING
TACTICS

 

We
intend to utilize the following marketing channels and tactics to position ourselves appropriately to prospective industrial hemp
business clients and customers. We believe that these strategies; social media and Netflix documental educational series will
ensure that our Company is able to generate a steady stream of new clients.

 

 

    	 	 	8 | Page

     

    

 

Online
Initiatives

 

		●	The
                                         REACH Genetics website, www.reachgenetics.com, will be the Company’s primary
                                         online marketing tool, and will be designed to serve as a powerful sales and promotional
                                         channel to reach our targeted industrial hemp businesses. The website will provide potential
                                         clients with key information that will enable them to make a positive decision and convert
                                         them into clients. The website will include:

 

●
An introductory video that grab the attention of prospective clients through explaining REACH’s service offerings and value
proposition.

 

●
A modern logo and typeface that makes the website easy--to--read
while establishing the Company’s brand identity.

 

●
An “About Us” section that will provide an overview of the Company’s history, background, and team Live Chat
/ Contact Form

 

Through
these initiatives, REACH Genetics will create a personal and memorable experience for the potential client, increasing the chance
of lead conversion and thereby generating potential revenues for the Company.

 

Search
Engine Optimization (SEO)

 

The
Company will utilize resources towards implementing an aggressive SEO strategy. REACH will work to optimize the search engine
rankings for all of its niche businesses. The Company will also focus on accumulating inbound links, listing on directories, instituting
a blog, and establishing a social media presence with the goal of achieving a higher organic Google, Bing, and Yahoo search ranking
for terms related to each of its different niche businesses. The organic ranking earned by REACH’s subsidiary websites will
bring authority to the Company as a leading and established industrial hemp platform and business. The Company will be very strategic
in the search engine keywords it optimizes for and will specifically focus on keywords that have low ranking difficulty and have
high purchase intent.

 

Pay-Per-Click
Campaign

 

REACH
will pursue a pay-per-click (PPC) advertising campaign in which the Company can pay additional funds for visible ads on search
engines like Google and Bing. These campaigns target high search volume terms relevant to the business in order to drive traffic
to the website. REACH must analyze and opt for keywords that are the most cost effective in terms of driving traffic to the website,
enhancing the Company’s visibility on the market.

 

In
order to do so, REACH will establish a Google AdWords account in order to create targeted advertisements that will appear on the
first page of a Google search. The Company can specifically create ad copy based on its targeted keywords, establish the geographical
radius in which the ad will appear, and allocate a certain budget towards that ad. When potential consumers search for a phrase
related to industrial hemp ancillary services, the ad appears near the top of the Google search page. When customers click on
the ad, a certain dollar amount will be removed from the Company’s allocated budget; this dollar amount will be higher depending
on the popularity of the search term.

 

    	 	 	9 | Page

     

    

 

Behavioral
Retargeting

 

In
addition to allocating a marketing budget to search and display banner ads, REACH will also aim to convert prospective clients
that have already visited one of its websites. A visit to one of REACH’s websites typically indicates a specific interest
in the Company’s service offerings. The Company will use its re-targeting algorithms to shift this initial interest into
multiple up-sells, cross- sells, and conversions.

 

Whereas
other sites are constantly marketing to completely new customers, REACH has already established a profile on the customer from
previous visits or visits to their other web properties to target the marketing to them based upon past activity or purchases.
The Company’s network of different properties will allow REACH to generate significantly more revenue from each customer
as compared to its competitors.

 

REACH
will also use behavioral retargeting on external websites. Retargeting marks online users who visited any of its subsidiary websites
with a pixel, and then serves banner ads on other websites visited by those same users. The cost of behavioral retargeting is
typically a fraction of traditional banner advertising. Assuming a conservative $5 CPM, REACH will show up to 10 impressions per
retargeted user, therefore spending $0.05 in the attempt to bring back a user with an existing digital profile back to one of
its properties.

 

E-mail
Direct Marketing

 

REACH
Genetics will hire a third-party company to gather email addresses for industrial hemp businesses across the country. Once it
has created a substantial email list, the Company will send email blasts to these prospective clients on a continuous basis to
direct them to the company website. REACH Genetics will also install a tracking code on all of its emails, similar to its retargeting
strategy, which will automatically drop an anonymous cookie in the visitors’ browser and create lists of people who have
visited the REACH Genetics website. The Company can then, again, utilize channels such as AdRoll and Bannersnack to identify previous
visitors and display retargeting ads on the web. Determine the Market and Content: Emails will include various types of content
that will attract and inform old and new clients; emails will be targeted and designed for specific markets. Email topics include:

 

		●	Informative
                                         Emails: These emails will include helpful tips and information. For example, one email
                                         may inform clients what services are offered and, on average, how much it may cost. These
                                         emails will spread goodwill to customers and enhance the Company’s brand.

 

		●	Value
                                         Proposition: These emails will inform clients on what makes REACH Genetics better than
                                         other competitors. The Company can highlight its experience, commitment to helping industrial
                                         hemp businesses grow their businesses, and overall positive ratings across online databases.

 

		●	Promotional
                                         Material: These emails will include discounts and promotions that can be applied towards
                                         the Company’s services.

 

    	 	 	10 | Page

     

    

 

Then,
determine Sending Frequency and Goals: After determining the type of content for the market or campaign, the Company will determine
the sending frequency and goals of the email campaign. By setting measurable goals such as amount of leads generated, the Company
can track the progress and success of the campaign over time.

 

Finally,
create Schedule: REACH Genetics will create a schedule for creating and sending out emails. Emails will be sent on a weekly or
biweekly basis, according to this schedule. In addition, the Company will increase volume of email blasts depending on seasonality
and market conditions. The Company can create email campaigns on platforms such as Mailchimp and Autopilot.

 

Referral
and Advertising Partners

 

We
will establish a multi-faceted referral system to acquire active partners and economic alignment with a variety of referral relationships.

 

●
Through banner advertisements on third party websites: REACH and its subsidiary companies will publish banner advertisements on
referrals’ websites that will direct viewers straight to one of the subsidiary companies.

 

●
High traffic, high following websites: The Company will utilize high traffic websites that have
a strong following to publicize REACH’s service offerings.

 

●
Channel partners: Channel partners can either be specialized or general websites focused on the
different sectors of the industrial hemp market. REACH Genetics will become affiliated with these channel partners and will offer
them a bonus when they recommend or drive a sale to a REACH subsidiary.

 

    	11 | Page

    	 

    

 

Offline
Initiatives

 

Events
and Trade Shows

 

The
Company will attend major industry event, expos, and conferences across the

 

United
States as it increases market penetration. The attendance of REACH Genetics at well- known events will help to grow the Company
brand, develop potential strategic partners with professionals in the industry, and generate additional leads for the business.

 

Examples
of Business-to-Business Events:

 

	 	●	NCIA
    (Oakland)
	 	●	West
    Tech Summit (San Francisco)
	 	●	Las
    Vegas Annual Cannabis Conference
	 	●	Big
    Show Industry (LA)
	 	●	NOCO
    (CO)

 

Print
Advertising

 

Print
advertising will also be an effective marketing campaign for the Company. This includes new feature, discount and product announcements
in local newspapers and publications, which will drive traffic to the Company.

 

Public
Relations

 

We
will focus on securing editorial coverage with various media outlets targeting the industrial hemp business market. The team will
reach out to relevant publication editors, high-traffic websites, and blogs in order to create a “buzz” about REACH’s
ancillary services and overall value.

 

The
Company will rely heavily on an innovative public relations strategy, building strong relationships with magazine editors that
focus on industrial hemp operators. The PR firm’s main responsibility consists of ongoing media outreach with top tier media
sources in the industry as well as prominent online sites and bloggers. Public Relations efforts will also include quarterly creative
programming ideas and pitches that will keep the Company in the media spotlight and provide the media with an ever-changing story
angle, increasing the Company’s opportunity for consistent media coverage.

 

COMPETITION

 

We
face significant competition in providing management consulting, business incubation services, and equipment, products, and technology
to companies in the legal industrial hemp industry that we are targeting. Many of these competitors have significant experience
in this industry, have been in operation for a greater period, and possess significantly greater resources than our Company. These
competitors may prevent us from acquiring desirable properties or may cause an increase in the price we must pay for legal industrial
hemp friendly properties. In particular, larger companies may enjoy significant economies of scale and therefore be in a competitive
advantage in pricing products and services.

 

Many
of our potential competitors are already publicly traded corporations, including companies engaged in real estate acquisition,
financial services, agricultural supplies, and legal industrial hemp growers and marketers.

 

    	12 | Page

    	 

    

 

We
believe that by targeting small and mid-sized producers and start-ups, which can benefit from our hands-on business support systems
and our variety of products and services, we have identified an under-served niche in this rapidly expanding industry.

 

GOVERNMENT
REGULATION

 

Our
business operations, as well as properties that we may acquire, are subject to many federal, state, and local government laws
and regulations, including land use, zoning, environmental regulations, operational licenses, and employment regulations. With
our emphasis on the legal industrial hemp industry we, or our clients and customers, will also be subject to significant government
regulations concerning the growing, processing, marketing, and distribution of legal hemp products.

 

Some
of the properties that we plan to acquire will be used primarily for the cultivation and production of industrial hemp and will
be subject to the laws, ordinances and regulations of the federal, state, and local governments involving land use, water rights,
treatment methods, environmental disturbance, and eminent domain. In certain jurisdictions, land used for agricultural purposes
are also subject to regulations governing the protection of endangered species and the protection of wetlands. Because certain
of the properties that we will own will be used for growing legal industrial hemp, some jurisdictions have additional regulations
regarding security and waste materials disposal.

 

At
the present time, under federal law legal industrial hemp plants are classified by the Controlled Substances Act (CSA) as a Schedule
I controlled substance. Even in those jurisdictions in which the growing, extraction, or sale of legal industrial hemp products
has been legalized at the federal, state and/or local level, the possession, use, transfer, and cultivation of legal industrial
hemp plants remains a violation of federal law. At present, it is the policy of the federal government, as stated by the prior
Obama Administration, that it is not an efficient use of federal resources to direct federal law enforcement to prosecute those
lawfully abiding by state laws permitting the use and distribution of industrial hemp. However, absent any statutory changes to
the CSA, federal law still criminalizes the possession, use, cultivation or transfer of legal industrial hemp plants and pre-empts
any state laws to the contrary. If federal law enforcement policy with respect to state-legalized legal industrial hemp plants
should change, such enforcement would seriously impact the business operations of our clients and customers, and thereby seriously
impact our ability to execute our Company’s business plan. Under such circumstances, we would likely suffer significant
losses with respect to our investment in industrial hemp facilities, including possible seizure and forfeiture of such assets.

 

RESEARCH
AND DEVELOPMENT

 

We
have had no research and development expenses since our inception in October 2015, nor do we intend to utilize a significant amount
of the proceeds of this Offering for research and development purposes. However, several of the entities that we plan to acquire
have undertaken significant research and development activities in the past several years which our Company, upon the completion
of our acquisitions, will benefit.

 

    	13 | Page

    	 

    

 

SEASONALITY

 

We
do not believe that seasonal factors will have a significant effect on our business operations.

 

EMPLOYEES

 

We
have had no employees since our inception, and all of our business operations have been conducted by our Officers and Directors
and Principals. Upon the completion of this Offering, we expect to employ 10 full-time and 6 part-time employees as part of our
expansion of business operations. In addition, as of March 1, 2018, the entities which we plan to or have already acquired employed
approximately 5 persons. Neither our Company nor any of our prospective employees are, or are expected to be, subject to a collective
bargaining agreement.

 

PROPERTIES

 

At
the present time, the Company does not own any real properties. The Company currently has lease agreements for office facilities
and warehouse operations.

 

EMERGING-GROWTH
COMPANY CONSIDERATIONS

 

We
qualify as an “emerging-growth company” as defined by the Jumpstart Our Business Startups Act (the “JOBS Act”).
As an emerging-growth company, we may take advantage of specified reduced reporting requirements under the Securities Act of 1933,
as amended, and be relieved of certain other significant requirements that are otherwise applicable to public companies. [See:
Risk Factors: Emerging Growth Company Considerations”].

 

MANAGEMENT

 

Officers
and Directors

 

Our
directors will serve until their successor is elected and qualified. Our officers are elected by the board of directors to a term
of one year and serves until their successor is duly elected and qualified, or until they are removed from office. Our board of
directors has no nominating, auditing or compensation committees.

 

The
name and position of our officer and directors are set forth below:

 

Ms.
Cynthia Boerum Chief Executive Officer, Chief Financial Officer

 

Ms.
Boerum became the Chief Executive Officer of the Company. in November 2017, after serving as Chief Operating Officer since 2016.
Ms. Boerum was Vice President of Sales and Consultant for Accentia International Outsourcing Company in Hyberdad, India, from
2009 to 2011. The leadership position included overseeing national and international sales teams.

 

    	14 | Page

    	 

    

 

Previously,
Ms. Boerum held positions of Vice President of Sales for Opus Healthcare in Austin, TX. 2004 to 2007 and positioned the company
for acquisition by NextGen. She also held the positions of Enterprise Vice President of National Accounts and Sales Manager for
the top 32 health organizations nationally at McKesson from 1989 to 2003. During this time, she received various top performer
awards, not only from McKesson, but also the state of Minnesota.

 

Mr.
Jeff Hranicka Chief Operating Officer

 

Mr.
Hranicka became the Chief Operating Officer of the Company in November 2017. Jeff joined Advantameds Solutions as the Capital
Investment Manager in 2016 and has successfully completed the NASAA Series 65 Uniform Investment Advisor Law Examination; selected
in June 2017 as Chief Technical Officer of REACH Genetics, Inc. Jeff is a proven business leader that delivers operational and
financial commitments while developing profitability improvements through organizational leadership.

 

Beginning
in 1998 he served multiple roles and was promoted to a Senior Sales and Operations Management Executive with leadership positions
of increased responsibility and complexity for WESCO Distribution, Inc. As Director of the WESCO Midwest Region, 2008-2015, he
led a world class sales organization approaching $200 million in revenues with responsibility for over 180 employees coordinating
multiple resources in sales, operations, finance, human resources, purchasing, pricing and marketing as critical components of
the field organization.

 

Outside
Directors:

 

Ronald
P. Van, Jr.

 

Professional
Summary: Mr. Van recently held the position of Vice President and General Manager, Central U.S. with WESCO Distribution,
Inc., a leading North American provider of electrical products and other maintenance, repair and operating (MRO) supplies. As
Vice President and General Manager Mr. Van led a sales organization approaching one billion in revenues with responsibility for
over 800 employees in 60 plus locations. He coordinated multiple resources in sales, operations, finance, human resources, pricing
and marketing. Mr. Van retired from WESCO in October 2015. He currently volunteers on a regular basis at PAWS Chicago no kill
adoption center.

 

Jeffrey
Stroin

 

Professional
Summary: Mr. Stroin currently holds the position of Vice President & General Manager with Turtle & Hughes, Inc.
He held the same position at WESCO Distribution, Inc. from 2005 through 2015. Previous to that he held various positions at General
Electric Company from 1979 through 2004 concluding as Vice-President Pacific Region. Jeff is a competitive, creative business
leader with 36 years of sales and management experience. He has a proven track record of driving profitable growth through strategic
analysis and execution of key business initiatives while managing electrical wholesale organizations as large as $900M and 850
employees.

 

Audit
Committee Financial Expert

 

Our
Board of Directors currently carries out the functions of the Audit Committee. Our Board of Directors has determined that we do
not have an audit committee financial expert on our Board of Directors carrying out the duties of the Audit Committee. The Board
of Directors has determined that the cost of hiring a financial expert to act as a director and to be a member of the Audit Committee
or otherwise perform Audit Committee functions outweighs the benefits of having a financial expert on the Audit Committee.

 

    	15 | Page

    	 

    

 

EXHIBIT
“A”

 

REACH
GENETICS, INC.

 

SHARE
SUBSCRIPTION AGREEMENT

 

Subject
to the terms and conditions set forth in this Agreement, the undersigned,                 
(the “Subscriber”) hereby subscribes for            
shares of the Common Stock, $.0001 par value, of REACH Genetics, Inc., a Nevada Corporation (the “Corporation”),
and hereby agrees to pay in cash therefore, immediately upon acceptance of this Subscription Agreement by the Corporation, or
at such other time and in such manner as may be agreed to by theCorporation, the aggregate sum of                
Dollars ($             ), representing a price of
$1.00 per share.

 

1
Representations and Warranties of Subscriber. The Subscriber hereby represents and warrants to the Corporation as follows:

 

(a)
Access to Information. The Corporation files current information with the U.S. Securities and Exchange Commission. Because
of the Subscriber’s business relationship with the Corporation and with the management of the Corporation, the Subscriber
has had access to all material and relevant information concerning the Corporation, thereby enabling the Subscriber to make an
informed investment decision with respect to his investment in the Shares, and all data and information requested by the Subscriber
from the Corporation or its representatives concerning the business and financial condition of the Corporation and the terms and
conditions of the Subscriber’s acquisition of the Shares has been furnished. The Subscriber acknowledges that he has had
the opportunity to ask questions of and receive answers from, and to obtain additional information from, the Corporation and its
representatives concerning the present and proposed business and financial condition of the Corporation.

 

(b)
Financial Sophistication. The Subscriber has such knowledge and experience in financial and business matters that he is
capable of evaluating the merits and risks of investing in the Shares, and he has the capacity to protect his own interests in
connection with the transaction.

 

(c)
Discussion with Counsel. The Subscriber has had the opportunity to discuss this Agreement and his investment in the Corporation
with his counsel, and to the extent it thought necessary, counsel for the Corporation.

 

(d)
Understanding the Investment Risks. The Subscriber understands and agrees that:

 

(i)
An investment in the Shares represents a speculative and risky investment, and there can be no assurance as to the success of
the Corporation;

 

    	16 | Page

    	 

    

 

(ii)
Subscriber can bear the economic risk of losing his entire investment in the Shares and Subscriber’s interest in other assets;

 

(iii)
The subscription price should not be considered an indication of the actual value of the Shares, and may not have any relation
to any applicable criterion of value;

 

(iv)
There is at present no public market for the Shares, and it is not known when or if a public market will develop;

 

(v)
Subscriber has adequate means of providing for Subscriber’s current and future needs and possible personal contingencies,
and Subscriber has no need for liquidity of Subscriber’s investment in the Shares;

 

(vi)
Subscriber does not have an overall commitment to investments which are not readily marketable, including the Shares and other
similar investments, disproportionate to Subscriber’s net worth or gross income;

 

(vii)
Subscriber is not currently nor has he ever been involved in any legal proceeding or circumstance, which would cause him to be
a “bad actor” under newly adopted Rule 506(d);

 

(viii)
Subscriber is a bona fide resident of the United States, maintains his principal residence there, and is at least eighteen (18)
years of age and is a United States citizen; and

 

(ix)
Subscriber is an accredited Investor, as defined in Rule 501(a) of Regulation D.

 

(e)
Understanding of the Nature of the Shares. The Subscriber understands and agrees

that:

 

(i)
The Shares have not been registered under the Securities Act of 1933, as amended (the “Act”), or any state securities
laws (the “State Acts”) and are being issued and sold in reliance upon certain of the exemptions contained in the
Act and the State Acts, and the representations and warranties of the Subscriber contained herein are essential to any claim of
exemption State Acts;

 

(ii)
The Shares are “restricted securities” as that term is defined in Rule 144 promulgated under the Act;

 

(iii)
The Shares cannot be sold or transferred without registration under the Act and the State Acts or unless the Corporation receives
an opinion of counsel acceptable to it (as to both counsel and the opinion) that such registration is not necessary;

 

(iv)
The Shares and any certificates issued in replacement therefor shall bear the following legend, in addition to any other legend
required by law or otherwise deemed advisable by the Corporation:

 

“The
Shares represented by this certificate have not been registered under the Securities Act of 1933 (the “Act”) or any
applicable state securities laws (the “State Acts”) and may not be sold, transferred or otherwise disposed of unless
a registration statement under the Act and the State Acts with respect to such Shares is effective at such time or unless the
Corporation is in receipt of an opinion of counsel satisfactory to it to the effect that such Shares may be sold without registration
under the Act and the State Acts.

 

    	17 | Page

    	 

    

 

(f)
Investment Intent. The Subscriber represents and warrants that:

 

(i)
The Subscriber is purchasing the Shares for investment for the Subscriber’s own account and not on behalf of any other person;

 

(ii)
The Subscriber is purchasing the Shares with the intent of holding such securities for investment and without the intent of participating,
directly or indirectly, in a distribution of such securities;

 

(iii)
Neither the Subscriber nor anyone acting on the Subscriber’s behalf has paid or will pay any commission or other remuneration
to any person in connection with the purchase of the Shares;

 

(iv)
The Subscriber has received no public solicitation or advertisement concerning an investment in the Shares; and

 

2.
Corporation Solely Responsible for Disclosure; No Independent Review or Opinions. The Corporation has assumed sole responsibility
for compliance with the disclosure requirements of federal and state securities laws in connection with the sale of the Shares.
No law firm, accounting firm, securities broker/dealer or other third party has conducted any due diligence review of the Corporation
and its business and affairs or any disclosures with respect thereto, written or oral, made by the Corporation or others. Notwithstanding
the preparation of any documents or agreements related to the Corporation or this investment, the Corporation’s law firm
has not rendered any legal opinions concerning any aspect of the Corporation’s business and affairs, including but not limited
to, the validity or enforceability of any contracts, agreements or obligations related to an investment in the Corporation. By
execution of this Subscription Agreement, Subscriber acknowledges that the Corporation is solely responsible for all disclosures
to potential Investors concerning the Corporation and its business and affairs and that no legal opinions have been rendered by
the Corporation’s law firm as described above.

 

3
Survival of Representations, Warranties, Covenants and Agreements. The representations, warranties, covenants and agreements
contained herein shall survive the delivery of, and the payment for, the Shares.

 

4
Notices. Any and all notices, designations, consents, offers, acceptances or any other communication provided for herein
shall be given in writing by registered or certified mail which shall be addressed to, in the case of the Corporation, at its
principal office address, and in the case of Subscriber, to the address set forth in this Subscription Agreement or otherwise
appearing on the books of the Corporation or his residence or to such other address as may be designated by him in writing.

 

    	18 | Page

    	 

    

 

5.
Taxation. The Corporation and the Subscriber may be subject to a variety of federal, state and local income or intangible
taxes, which, in large part, will be based on the individual circumstances (including income from other sources and performance
of other investments) of each investor. Because of these and numerous other variables, it is not feasible to present a detailed
explanation of the tax treatment of an investment in or ownership of the Shares. Accordingly, the Subscriber will consult its
own tax advisor with respect to its specific situation.

 

6.
Miscellaneous Provisions.

 

(a)
Headings. The headings in this Agreement are for convenience of reference only and shall in no way be deemed to define,
limit or add to any provision of this Agreement.

 

(b)
Amendment. This Agreement may not be amended except in writing signed by the parties hereto.

 

(c)
Severability. The invalidity or unenforceability of any particular provision of this Agreement shall not affect any other
provision hereof, which shall be construed in all respects as if such invalid or unenforceable provision were omitted.

 

(d)
Binding Effect; Governing Law. This Agreement may not be assigned or transferred in whole or in part by the Subscriber
without the prior written consent of the Corporation. This Agreement shall be binding upon and inure to the benefit of the Subscriber
and his estate, heirs at law, legatees, distributees, executors, administrators, other personal representatives and permitted
successors and assigns, and shall be binding upon and inure to the benefit of the Corporation and its successors and assigns.
This Agreement shall be governed by and shall be construed under the laws of Nevada.

 

[Signature
on next page]

 

    	19 | Page

    	 

    

 

IN
WITNESS WHEREOF, the Subscriber has duly executed this Subscription Agreement as of the date set forth below.

 

 

	 	SUBSCRIBER:	 
	 	 	 
	 	Name
    of Subscriber: 	 
	 	 	 
	 	 	 
	 	Signature
    of Subscriber	 
	 	 	 

 

	 	Address:
    	 	 
	 	 	 
	 	 	 	 
	 	 	 
	 	Taxpayer
    ID No. 	 	 

 

	 	Dated:	 	 

 

	SUBSCRIPTION
    ACCEPTED:	 
	 	 	 
	REACH
    GENETICS, INC.	 
	 	 	 
	BY:
    	 	 
	 	 	 
	NAME:
    	 	 
	 	                   
    	 
	TITLE:
    	 	 
	 	 	 
	DATE:
    	 	 

 

    	20 | Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]